Diagnostics & Drug Development

Diagnostics & Drug Development

From first-in-class allergen platforms to pre-clinical biologic programmes, HH Global Holdings designs and delivers diagnostic technologies and drug characterisation programmes that move science from bench to clinical or commercial readiness.

Case Studies & Track Record

Diagnostics & Drug Development

Selected examples of our work in diagnostic platform development, IP commercialisation, and pre-clinical drug characterisation programmes.

STATUS — Concept
Diagnostics Platform · IP Licensing

Multiplex Allergen LFT, First-in-Class Platform for Global Distribution

A single-device lateral flow test that detects 13 of the 14 EU-regulated allergens in 15 minutes, no instrument, no laboratory required. HH Global Holdings retains full IP and is in global licensing discussions with a major international diagnostics manufacturer.

STATUS — Active
Preclinical Development · Drug Characterisation

Biologic Drug Characterisation, Pre-Clinical Programme

An end-to-end pre-clinical programme that characterises a biologic drug, establishing what it is, how it works, and validating its efficacy, readying the asset for clinical entry, partnership, or licensing.